N
Google TrendMONTEZ SWEAT (1000+) — Bears DE Montez Sweat suspended 2 days for drug violation
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:montez sweat1000+rob lowe1000+tanner hudson500+frozen frenzy200+payton pritchard1000+huevo500+winter weather advisory2000+joão cancelo1000+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "FDA Approves Tafasitamab" (30 stories)

Top Headline Story

Tafasitamab-Based Regimen Scores Australian Approval for R/R Follicular Lymphoma
Lead StoryOncLivegeneral
Apr 23

Tafasitamab-Based Regimen Scores Australian Approval for R/R Follicular Lymphoma

<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxQUE9zNWdFblI2dlZmRG9ocy1vY0VHUHhzSHBQMlpPTVJrbF9OTU55UzRCMDhRT1FmQlMyYnVWNk1pR2s5VFlnUVc5N3dXdFZYUE56NGhiVEc1OWV0SDJDbjYyYl80VHZNQUNrdnQ2N0xWOWxMX3pHcC0yRzZOejhiVzE3UWlLRWVoNVRobzl0SHVscW0teUJlR0dSa00xeWFLRUxqbnhkOWsxMzdqOWc?oc=5" target="_blank">Tafasitamab-Based Regimen Scores Australian Approval for R/R Follicular Lymphoma</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
1000+18m ago

montez sweat

Bears DE Montez Sweat suspended 2 days for drug violation

Filter stories
1000+28m ago

rob lowe

Daily Wire's 'Confession': Details Revealed For James Franco, Rob Lowe Film

Filter stories
500+28m ago

tanner hudson

Bengals tight end Tanner Hudson out for season with torn pec

Filter stories
200+28m ago

frozen frenzy

The top reason to watch every NHL team in the Frozen Frenzy

Filter stories

Search Results for "FDA Approves Tafasitamab"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed
European Commission Approves Tafasitamab Combo in R/R Follicular Lymphoma
CancerNetworkworld

European Commission Approves Tafasitamab Combo in R/R Follicular Lymphoma

<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxPTXRNM3AtUVlUR1V2RjFvVWdrdk5Da1dpcm1JdU9lUlV3VWpla1dfZUlZYkNmVUJqcFJUWkxUcmtZbFFHWXhROUp0RHMzTXYtV2pqLTNJZXFScDhJdmhMMlF1eTVxb0JHc19oVWpyR3FvazVYSENXWGxQcEpONmlFd1NIRXZFSVg3WFNDOTZXdFZCMW9HYjVQdkZfSWNXREE0cW83cnpOM0V1REtG?oc=5" target="_blank">European Commission Approves Tafasitamab Combo in R/R Follicular Lymphoma</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
FDA Approves Epcoritamab Combo and Monotherapy for Follicular Lymphoma
Oncology News Centralgeneral

FDA Approves Epcoritamab Combo and Monotherapy for Follicular Lymphoma

<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxNd05lbFZ2U1UwRVVCZVlobV93V0JHTFlaU2JiUXZ4Si1tZ0V0Rkx0dm5pa0ZPQm1rbGg2SmZnYlNkLVJ0ejJ4MFo4Qy1mc1liNXVuQ1V6U0VXNWRkTHlud2I1UkRZdndUMk1Ua0NpaG5laGxsUDZGRHVmRmZuUmxBSUIzTlIydTBqV016NThLVUtxazA4bndNcVRGTklLVmpYQzlnaG9qMTgzbkpyZkhlbjdVa1RReEhy?oc=5" target="_blank">FDA Approves Epcoritamab Combo and Monotherapy for Follicular Lymphoma</a>  <font color="#6f6f6f">Oncology News Central</font>

Read Full StoryMore like this
FDA Approves Tafasitamab-Cxix (Monjuvi) for Relapsed/Refractory Follicular Lymphoma
Lymphoma Research Foundationgeneral

FDA Approves Tafasitamab-Cxix (Monjuvi) for Relapsed/Refractory Follicular Lymphoma

<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxOSnlDVkdJZWY3WGJ0VVdja0Y2cG13T0ZPVTdubmxyYWpzejlZSldOakNJc3A1ci00ZzM2X2RfbjV2NzMybi01RERPZWh2Y2d5WEloRzFiOE9NYTZMeUppbEFubm42VWJDZ0plUkF2MzZFdkdZZmZfckVaX1BFWExYa2JEc2t3Z3pWd1daOW56UEdha3pmcmRFSmZwS2lQaGJMbWtERVZESkFvZHZn?oc=5" target="_blank">FDA Approves Tafasitamab-Cxix (Monjuvi) for Relapsed/Refractory Follicular Lymphoma</a>  <font color="#6f6f6f">Lymphoma Research Foundation</font>

Read Full StoryMore like this
Tafasitamab Plus Rituximab and Lenalidomide Wins Japanese Approval for R/R Follicular Lymphoma
OncLivegeneral

Tafasitamab Plus Rituximab and Lenalidomide Wins Japanese Approval for R/R Follicular Lymphoma

<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxQdXh1RWxlcGZ6REJmNklTVG5JenRrdUtqRmt1OWNvQ2FmUHVpdl84ZFVPT2MwamlzZlhWLS1qVzVJUmNUbXVpcElTTkpFNk1KbzFDN3BFdWJGR3M2VTFrd19Va29fVHB1a3BrcnRqdW5kQVRQd1NVWWprdkF1Vjc1SGNiUmI3QUMtZHZSdU5Pb0QzMU5PdnpOemUzS2tkUzE3MVp5UWJpN0x5WENBdUFmaFNvemNRNm5GeUlyNm82bkI?oc=5" target="_blank">Tafasitamab Plus Rituximab and Lenalidomide Wins Japanese Approval for R/R Follicular Lymphoma</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
FDA Approves Tafasitamab for Follicular Lymphoma
The American Journal of Managed Caregeneral

FDA Approves Tafasitamab for Follicular Lymphoma

<a href="https://news.google.com/rss/articles/CBMif0FVX3lxTE1Rc2szOTMyVEU5aTduS2Zxc2dGOEZxTV95T2JMZkZXVUVwbzVveTQxOXdVdFBFS1NSYXdOaGtmRkZTZEsza3h2TlE2bzdpX29ObC1vOHFwX2otNHZQTVFONHZtZWpLRkxCMHZDTFVMbXExYUZ5QjZaUVFpQWE3S2c?oc=5" target="_blank">FDA Approves Tafasitamab for Follicular Lymphoma</a>  <font color="#6f6f6f">The American Journal of Managed Care</font>

Read Full StoryMore like this
FDA Approves Tafasitamab in R/R Follicular Lymphoma
Targeted Oncologygeneral

FDA Approves Tafasitamab in R/R Follicular Lymphoma

<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxNZ0FLQWJNSzRZbGFVWkNXMi1ORzU1aDlsTFMwS0RtWFFjTXo4aDJaS0lMN2J2MFRrQk1iVmdfSUJlX0l6QzhMUGw5bjVfX0M4R2FwZEJmUkQ5UDgxTWhTZ2ZLWENLaWIwamNsc1g1YldUNHFqdi1LSHk2bFp2UmlUV3QzbHltYjNvOWtYVg?oc=5" target="_blank">FDA Approves Tafasitamab in R/R Follicular Lymphoma</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
FDA Approves Tafasitamab Combo for R/R Follicular Lymphoma
Oncology Nursing Newsgeneral

FDA Approves Tafasitamab Combo for R/R Follicular Lymphoma

<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxPMnRrY0oxRmNVd19jNXNaaERPX0ZrOGJsYjNHVEp3RmhSdTEzbVFYQ1luLUVIQTRoUVhreWhnY0dRRl9kY1lsY2JCZXk4eVdIb0cwazVGR1d4MTUzbFVSSzN6NE5zN2lVbUJ0RnlWZDZZVzRkM1dEOFpwbnR4VzBpUEoxcXdhb2dMZk5FUHdWaG9raUFaMkNjLTJn?oc=5" target="_blank">FDA Approves Tafasitamab Combo for R/R Follicular Lymphoma</a>  <font color="#6f6f6f">Oncology Nursing News</font>

Read Full StoryMore like this
Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma
Business Wireworld

Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

<a href="https://news.google.com/rss/articles/CBMixAJBVV95cUxPUEhDbndydUdZM3RPOGQxdTdkb2xHUGtsY3NjYlA5ZG9Dc1NLNTRqVTVNM19TLWIxNXFEN3EyWGJPVlc2al9KQVRpMlYxX3pJY3Nia19yU0g4dDBRUFFfOTZvNVlDb3BRV19rU1ZueVZpaGpfZGZDbE5rdDBCcnlLaEJqOWppTEJzZE8yX1hSTE5acFBxYUNOTmFTSUtwY2N2X1BpMkd2WkFFN1dhUm96UnpqOVVzUDdmbE9ZNmp0eWp2N0Zudi0xekFDWWRvb3lsOUNQN2M4dWZyaGl0QnNybEJOdy1qV3o3dnl5T0ZJNnF3dHBqNEhpZUlJVU5DemZaWEN5U0FaeG9LN1FLWGhhTjZNM2RlLVZlNmhSYzBaS0l6MzZiejJUanpoN21TRS1aNUc2TmdEckRZOVZBdUJnMUJRYTg?oc=5" target="_blank">Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma</a>  <font color="#6f6f6f">Business Wire</font>

Read Full StoryMore like this
Tafasitamab in combination with rituximab and lenalidomide approved by the FDA for patients with R/R FL
Lymphoma Hubgeneral

Tafasitamab in combination with rituximab and lenalidomide approved by the FDA for patients with R/R FL

<a href="https://news.google.com/rss/articles/CBMi3wFBVV95cUxNaHV2NmF0SjNla1oxYkltYjZPcHJTN2U2ODBkbzByMnZaeFItZG1CbnYxWWwycm8zazEyV3BreUJUUEhSOG1XVlFTMEZEd0ZqSGNPUlZ1WFBVZ3pKdnlwUkI5MkRVT0JWV3dKM0N6a19GcHNaOHNYRnlZTHNKU1JqVXVFUW1tU0JtaXd2SWdrbW11YmpoWXM0QlltcEJ3RWJVVS04NzA5UjVObm9YWVRSX1luY3VNSXdCeUFhcTFBR2NoWVJOSENCUm1SNHFQRDNteXJWM1BqeWU5SU5xeUNn?oc=5" target="_blank">Tafasitamab in combination with rituximab and lenalidomide approved by the FDA for patients with R/R FL</a>  <font color="#6f6f6f">Lymphoma Hub</font>

Read Full StoryMore like this
FDA Approves CD19-Directed Antibody–Based Regimen for Follicular Lymphoma
The ASCO Postgeneral

FDA Approves CD19-Directed Antibody–Based Regimen for Follicular Lymphoma

<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxQV0I4VkJmZXlEbDFFc0FkMG5ESlpjb3ZTeFZfSW85dUZ0RlpNTjhqX3JmMHJMZ1BnbHZNcjhLQmxMZmltcW5lbkdZb01la01UTF9aNWJ3UHUtWGJjS1VPMnNrNkJ1b3FFZ1EyYnlJN2lYRGxJNV8tclBZX1RBUFUxbU83TGhydDJuem01R3VKdUJZQU9tQlh0blZ6NWx1UG1UQ1ZoajdTTHNFWk14NGN3?oc=5" target="_blank">FDA Approves CD19-Directed Antibody–Based Regimen for Follicular Lymphoma</a>  <font color="#6f6f6f">The ASCO Post</font>

Read Full StoryMore like this
Tafasitamab-Cxix With Rituximab, Lenalidomide Approved by FDA for Relapsed/Refractory Follicular Lymphoma
Pharmacy Timesgeneral

Tafasitamab-Cxix With Rituximab, Lenalidomide Approved by FDA for Relapsed/Refractory Follicular Lymphoma

<a href="https://news.google.com/rss/articles/CBMi1gFBVV95cUxQcE5OQUNEX2VpempTS2tBQ1FHanZzLXJzNWk2TnRreEVwcEM0eUROTDV3ZlpBNnhDdkgtWnQyWVYxa29vYnVGcDg1N1pNS21tZzhiaVk5c1BsME55V3V2OEpGVlRHQUI0NjdwSlpsR1RxaGlrTmlwbWd0amZIc1FyQi10UjJTZ1dYRVFGei1kdm96NXB1THlUcVRoM1YxZ3c1bDg3UVNVakZBRG5GTm9ieWh0YXgxVkQybDhFQ1NMbzZ5YnoxT0dyVXBWWWhBMlFjSk42LTFn?oc=5" target="_blank">Tafasitamab-Cxix With Rituximab, Lenalidomide Approved by FDA for Relapsed/Refractory Follicular Lymphoma</a>  <font color="#6f6f6f">Pharmacy Times</font>

Read Full StoryMore like this
Tafasitamab Combo Receives Japanese Approval for Relapsed/Refractory DLBCL
CancerNetworkgeneral

Tafasitamab Combo Receives Japanese Approval for Relapsed/Refractory DLBCL

<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxPRGMwaVBQalptQkhRR0oxM0lZTHRYa2Fvc0FXS01XdGxNZHhvclpXREttRGhxa1NuS3kwME1mekZ0bmJKSWozckt0SHRJUXk5Nk5xUGxSZWpqQkYySkdGdXBVb1ZKMGNmVjVWYUpMMXNSMEY2aFdjQ1NkUEIxVGlHNkxqeXNYal9kZEcyZEZwbUJKWFlGUmhwdlNjMmFvWGliSTBKem40dzJLQ2dmSkE?oc=5" target="_blank">Tafasitamab Combo Receives Japanese Approval for Relapsed/Refractory DLBCL</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
FDA Approves Tafasitamab (Monjuvi) Combination for Follicular Lymphoma
Oncology News Centralgeneral

FDA Approves Tafasitamab (Monjuvi) Combination for Follicular Lymphoma

<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxQMlVZWTVKUWE1a0JKRDMwWi1aalF0QklndWgzQ1Vodm5WZVE2cVh6Ti12alI0dlVlYk4zU1Q0Qk9kbkhmTnkxSjZ1TUk5cS1IXzN5bUdtSTM5aFFjWVZPNnAyTUhzb1B2VnRiaXZWLXAta212Y19EaldIVk9NT1JicGJFa2lrc3RuLVA0QTlhazE3WGZkMlNQM0REd3ZucVNqRFZhc210OWdHXzg?oc=5" target="_blank">FDA Approves Tafasitamab (Monjuvi) Combination for Follicular Lymphoma</a>  <font color="#6f6f6f">Oncology News Central</font>

Read Full StoryMore like this
Tafasitamab Plus Lenalidomide and Rituximab Nets European Approval in R/R Follicular Lymphoma
OncLiveworld

Tafasitamab Plus Lenalidomide and Rituximab Nets European Approval in R/R Follicular Lymphoma

<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxPb1dhcl91SFpIcDFqSHI2cGk0SEZzdDh0SG1ESE1KUVZJQllrQ2ZiSEdBLXpwcUNJSnVsZXpZZzRQcDkyMElWTGVvdHhRWklhWXQ5b3JiTXAzS0tvSUgzaEx0NE0wRXJIM2RrR3NGSUFkRDN4WmtxQjhpSm5LaUZST1h4ZXk2dXBXOWl4Y3RRRWlnZnBNSkF4WFJSa09XanI1UnZ4T0VsTWFlRlRQUVJmNlEzd0IzUkItOUdKdFNLNA?oc=5" target="_blank">Tafasitamab Plus Lenalidomide and Rituximab Nets European Approval in R/R Follicular Lymphoma</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
FDA Approves Tafasitamab Combo in R/R Follicular Lymphoma
CancerNetworkgeneral

FDA Approves Tafasitamab Combo in R/R Follicular Lymphoma

<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxPZTdkY2pWVUJmUkZRYUl1MF81Z1VEVVRtYm5LS0x5bW41SGVCZFU4RjZ5UHlERTFfa1ZPTGFCUzIwcllYdWJFa0xSS1VVR0ZlM1RWbUl3S0pXTUZKb2JzQ19JbzI5YllUeklFRGtyNmx6RDZTVTVmWHJQOVMwblFTZ3ZtVGt6Snp6SkNfamx6VkZfVWlyM3JF?oc=5" target="_blank">FDA Approves Tafasitamab Combo in R/R Follicular Lymphoma</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
FDA Approves Tafasitamab Plus Lenalidomide and Rituximab for R/R Follicular Lymphoma
OncLivegeneral

FDA Approves Tafasitamab Plus Lenalidomide and Rituximab for R/R Follicular Lymphoma

<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxONE1xWU81NmNxS1lsRU1qT3Z4d2hyQjVjTnpua1RCNHVQUElRTENJVEJLQU9oNWtNTU5lQ1JvV1dwZVNLaW53R0d0WDRZMlhvUGhmaUhpb1JlZzdUNTQ0N1NUMDdkRGMtUGdLUXNtVDNDQ0pvY2ZWYmt5YWIzaEs3NzR1YVZaUF9Pb0NDMHBqUTMwZUk5dnFTb0V4YmRMMGJxQU1Ec3VaeWUweU90Q2RKYm9Taw?oc=5" target="_blank">FDA Approves Tafasitamab Plus Lenalidomide and Rituximab for R/R Follicular Lymphoma</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Tafasitamab/Lenalidomide/R-CHOP Improves PFS vs R-CHOP Alone in First-Line DLBCL
OncLivegeneral

Tafasitamab/Lenalidomide/R-CHOP Improves PFS vs R-CHOP Alone in First-Line DLBCL

<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxQdXJHbXBiMEZKUVJqemxneVpMTVJfMTAwYkZ2YlMwNmVadV95SzhKNFlodDhwbzJTc3M1MWd6aTFlSzVsbGFwMkk4V011RWFBMGR0ZWFuWm85b0xwZUcwY0h3SGQ1TGxENnU2ZlZwMVRDdDYtSW1uTEp0djNJWjl3WHN5Y29QQ1dfM1FrUHBJWHZQTUJMWjk5SWZaRXd3VkhtWFU4ZHZjWFFlRURJbHc?oc=5" target="_blank">Tafasitamab/Lenalidomide/R-CHOP Improves PFS vs R-CHOP Alone in First-Line DLBCL</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Dr Gopal on the FDA Approval of Tafasitamab in R/R Follicular Lymphoma
OncLivegeneral

Dr Gopal on the FDA Approval of Tafasitamab in R/R Follicular Lymphoma

<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxPT250WnVLanlPZDBnRUxBMUVxdjdaRmJya1VIMmJXTXltNE93b2lDSGx0WVd2WmpiT2NvcjBEQzVxNmxVUTYzMW8zZjg4b29tSElIZGl6aWx6Z1Y2amJacEhzajVONUdxSy1RX25rdlZIeGlpdldKQ3psOW9uUmdGcEYyV19ZQXZYcUJxQVpiaU93d2hqTGMtWEdid1pqeFRK?oc=5" target="_blank">Dr Gopal on the FDA Approval of Tafasitamab in R/R Follicular Lymphoma</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
FDA Approves Tafasitamab Plus Lenalidomide in Relapsed/Refractory DLBCL
OncLivegeneral

FDA Approves Tafasitamab Plus Lenalidomide in Relapsed/Refractory DLBCL

<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxQdlFxcVE0amNWUTlSTXRTOW4wNnpjUmxsbWIyVjYwaW5LZlJlSTZrSzdBZ2VYZ3VnMWhHOXExZ3RQRVdwUFV5cl9MVW5IQWphWHo0eENLeDhTS2d5WUY2SjdKTU1EanQ4OUhfU1pKUGUyZTBlTkZwQ0h0bXlxbTc5RmRKUENNaDktSm5tZWJQb0dWeExZWTIyVjVTdmR3WlJNQUE?oc=5" target="_blank">FDA Approves Tafasitamab Plus Lenalidomide in Relapsed/Refractory DLBCL</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Oncologists’ Guide to the FDA Approval of Tafasitamab for Relapsed FL
Targeted Oncologygeneral

Oncologists’ Guide to the FDA Approval of Tafasitamab for Relapsed FL

<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxPeVJTdWJrNGZVdmQ5Qk1UOHRBdVRuSWRPSktNOXJJbGR3blNjYlBlRlk3UTI4NEZIME4xcXdKMnpWSzJ1aUdfWDcxYVZ5LTJjV1otS3hERzZhdTJTdlRnYkwySHVEVnJLeEFSTE1KWFB3S2ZmblZuRnpXOHhKTHhiaFcwd3dGX01hZXNNcTJqX01IUkdnTGNKOWNzUU8wZWJIQmlF?oc=5" target="_blank">Oncologists’ Guide to the FDA Approval of Tafasitamab for Relapsed FL</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
Dr Mehta on the FDA Approval of Tafasitamab Plus Rituximab/Lenalidomide in R/R Follicular Lymphoma
OncLivegeneral

Dr Mehta on the FDA Approval of Tafasitamab Plus Rituximab/Lenalidomide in R/R Follicular Lymphoma

<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxPb1hfNDNGYXg0SFRNWEx4RUFQTVhRdFc3SXQtd0ExWE9JbTNWbjdLUy1WT2pIdHdGTTdTRkdQS2R3dWp3Ymxoa1VMS2hSbkotbE00QXhuOXVma2xISVNYd2RMN2dxM01naWt2c29BZS1YeUQxemVadXZBeS1VYWJGZHN3b3pyM1ZuNmtPTHpFcTRFMmtDZzBsTF9pWGNEaXMwV25iQ1NWYm96QnlxYmNnOFZEaWdMT0lObEhKcUFvNm1tZw?oc=5" target="_blank">Dr Mehta on the FDA Approval of Tafasitamab Plus Rituximab/Lenalidomide in R/R Follicular Lymphoma</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
FDA approves tafasitamab in combination with lenalidomide as second-line treatment for patients with R/R DLBCL
Lymphoma Hubgeneral

FDA approves tafasitamab in combination with lenalidomide as second-line treatment for patients with R/R DLBCL

<a href="https://news.google.com/rss/articles/CBMi6AFBVV95cUxNTFQ1MVZTaXNCdEtncldZT3FIaEpudUc0OE1aekw3LVgyMC1vYjMzd0VyOERBVGVLTmpaNE56NmRUZm82dDBiYXFvQklSNzlNdlQ0dXZabDZxaU1xMnhLM2RxbjBmazFwdFBiTEhmTWpWTzByZEVrQm9lZXlBTm5FTTJQakhUeV9ra3JMcEVrMGZ3NlJvU0pmQzZFVHJKeTdGbUV6RXY5NGNZY1I5eWRrM2VjenlmQ3hPeFJCLTJydVlVZmVtLXd6ckl1Wl93ZFJjUmRhR0NHTEFyclpTN2x4X1JoVUoxbTBy?oc=5" target="_blank">FDA approves tafasitamab in combination with lenalidomide as second-line treatment for patients with R/R DLBCL</a>  <font color="#6f6f6f">Lymphoma Hub</font>

Read Full StoryMore like this
FDA Approves Incyte’s Monjuvi for Relapsed or Refractory Follicular Lymphoma
Pharmaceutical Executivegeneral

FDA Approves Incyte’s Monjuvi for Relapsed or Refractory Follicular Lymphoma

<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxOaHk4OTZXbjMzTmdLc2NrZGJPMXgxb1lrbjJrYkJBaUx5WlZqQzRydTYxN2UxYktlNl9hT3ZCOV9Vc1JCdV95TW9kNVc3dEVKb3R5WmtpWU8zLUxyck1qVXFBZ1hOb2gyRGNfWXBPeVNTVUltd09EcEhtTV94U0pMZkRTRktwdHg5OVFhZ0QzNVdRRzdMQlNWeE05b2Z6WUk?oc=5" target="_blank">FDA Approves Incyte’s Monjuvi for Relapsed or Refractory Follicular Lymphoma</a>  <font color="#6f6f6f">Pharmaceutical Executive</font>

Read Full StoryMore like this
FDA Approves Tafasitamab, Lenalidomide Combination to Treat Relapsed/Refractory DLBCL
CancerNetworkgeneral

FDA Approves Tafasitamab, Lenalidomide Combination to Treat Relapsed/Refractory DLBCL

<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxNNzlEZkFmeUgtOHgwQTNBMXFrQXQ3N2d0bUtWU2dHLTB4Y25SOFRzVmpOU01QT0NNRHM0VlhuRnpKYjJzZnhjUjl0LThoQUZIZkpMdU1IR09GcXhsQzN4Zks5WEdqVENnUUZwNFZ4dFlvbWtvcGJoakZKUG5PeW9kY2RvNk5ETGpUSUViUnBaMXN6VkZNRVlWazRqQkVGQkk1WE1wMGctN0Y4bkNQQVdVX2lwOTdjOWFVVzEw?oc=5" target="_blank">FDA Approves Tafasitamab, Lenalidomide Combination to Treat Relapsed/Refractory DLBCL</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
FDA Approves Monjuvi With Revlimid and Rituxan for Follicular Lymphoma
Cure Todaygeneral

FDA Approves Monjuvi With Revlimid and Rituxan for Follicular Lymphoma

<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxQMlRzOUdETkhlb3lTUDVjbFc3YUdDS2lPNUQybmFGcmt4ajdCVnkxc2NqM205QkpCTDhzRlZOVlJlVVZoaXVzRXU3Vlp0SzBBa2xqNk43bUVHT01fdnJ2Snc1UHBEQmQtM1VCWVpYd1AtVC13UW9tTG9FR3lhUVc2T0VXYmtZYkpMOHh6QUg5TVByOGIwWW1jRDF6WXNUQk5kQ2xZ?oc=5" target="_blank">FDA Approves Monjuvi With Revlimid and Rituxan for Follicular Lymphoma</a>  <font color="#6f6f6f">Cure Today</font>

Read Full StoryMore like this
FDA Approves Monjuvi, Rituximab and Lenalidomide Combination for Relapsed or Refractory Follicular Lymphoma
Managed Healthcare Executivegeneral

FDA Approves Monjuvi, Rituximab and Lenalidomide Combination for Relapsed or Refractory Follicular Lymphoma

<a href="https://news.google.com/rss/articles/CBMi6gFBVV95cUxNYy1kMkN0akI4aHFiV0ZmT05vUm04NWRkME5jZUNGVnBqcHBHU1M4c08wTVhOUWVyYWZKUDBrcmdjTzlIbmFCQ3ZZVTRzNlVkSEtqVWdTaWpRR3BXOUFyb0h2cEZHTmZ5Z0hyb1NEY0ZOOGIwWHBPVTZFU2wyb3NzV0oydTJ4ejRpaF85RFFyTGgwamxjUFZXNHJzb3NBd2tLTFBQMTlOY3NyZEI5b1JFcU5VT2hYMzZPREw2ZHRYTEFnTi1ycEdrMTY2X25JZjdIZmNBUzR4ekx1UXBrcWlITVR1YWttR1ZvQ3c?oc=5" target="_blank">FDA Approves Monjuvi, Rituximab and Lenalidomide Combination for Relapsed or Refractory Follicular Lymphoma</a>  <font color="#6f6f6f">Managed Healthcare Executive</font>

Read Full StoryMore like this
Tafasitamab Approval Expands Chemotherapy-Free Treatment Options for R/R Follicular Lymphoma: Christina Poh, MD
The American Journal of Managed Caregeneral

Tafasitamab Approval Expands Chemotherapy-Free Treatment Options for R/R Follicular Lymphoma: Christina Poh, MD

<a href="https://news.google.com/rss/articles/CBMi0AFBVV95cUxNUEw1cTlEUTdxVWFwc2ZoNmM1SE9NbTFDVmN6WEo3ZldFUEFzaFVaLVl6c3pFWUhGYjA0OTRLTFJmSWotWU1NNXNPTkczMzVPeWF5ZGZfMHI2M0s0Qy1XSzhxV0dGTm5SZlRUU1ZJeVY1X2VjRDdwUWpWX0FzOFVPOUozMkYxVnBQa3g5MWV5UkUzUDR1MU1YQXVvQ2laOC1GNExZQ19vdjlwZENxR1ktaXdQRVNUTUdsMFVEUmZteWhSWk9JblJKM0haMm91LTht?oc=5" target="_blank">Tafasitamab Approval Expands Chemotherapy-Free Treatment Options for R/R Follicular Lymphoma: Christina Poh, MD</a>  <font color="#6f6f6f">The American Journal of Managed Care</font>

Read Full StoryMore like this
FDA Expands Monjuvi Approval to Include Relapsed or Refractory Follicular Lymphoma
news.cancerconnect.comgeneral

FDA Expands Monjuvi Approval to Include Relapsed or Refractory Follicular Lymphoma

<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxQOTgxcDJia09iUTd2R3ZrcTFudW9GanJnbkZVM1V3X2JwbzRmaWFmQlMxZ2VLVE5CT3lYV2Y2Si1pYmxiakRUejhoQmRwNHpqNWRnU2sySjBoTEJPT2Q1V01XN2tnNmstc3hlMWU0dlBjUGZ4X3NiTHREY3R5NnA1MXc0NjI0UDZyX0tWZUtKRjVqYUthU2hxSGxLWHNmbTNLNzBVRENBZEhpbFRLVFJNWXhiV3g?oc=5" target="_blank">FDA Expands Monjuvi Approval to Include Relapsed or Refractory Follicular Lymphoma</a>  <font color="#6f6f6f">news.cancerconnect.com</font>

Read Full StoryMore like this
Tafasitamab Approaches EU Approval for Relapsed/Refractory Follicular Lymphoma
OncLivegeneral

Tafasitamab Approaches EU Approval for Relapsed/Refractory Follicular Lymphoma

<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxQT0g5b1UxcUJNY3hQM0RKLWZRbUdYWFRzZXpKRE5Hdm8zMFlXX0pyczdKbDNvbXMtWlR2MDRKOVlQOVVZblVSQzZvREdiR0FjWWw4S3EwZFhKdUdJdE8yV0tCRm55cnpXZ2Zic3JSamIzbzRPbUNxUEN4OWNOZWx5cHFka09oQVBmMEhtNi1fZ1NNVk14M0pUMWpCUG9sMVhJdDRpUS1oU2V4Q00?oc=5" target="_blank">Tafasitamab Approaches EU Approval for Relapsed/Refractory Follicular Lymphoma</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
"FDA Approves Tafasitamab" — Live Google News Trends & Headlines